Vor Biopharma (VOR) Total Liabilities (2020 - 2026)
Vor Biopharma (VOR) posted quarterly Total Liabilities of $657.2 million for Q1 2026, up 1419.71% year-over-year from $43.2 million in Q1 2025, and up 4.57% quarter-over-quarter from $628.4 million in Q4 2025.
Vor Biopharma (VOR) Total Liabilities (2020 - 2026) Analysis & Trends
Vor Biopharma (VOR) has reported Total Liabilities for 7 consecutive years, with $657.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Liabilities rose 1419.71% year-over-year to $657.2 million; the TTM figure through Mar 2026 stood at $657.2 million (up 1419.71% YoY), while the FY2025 annual figure was $628.4 million, up 1259.46% from the prior year.
- Total Liabilities grew to $657.2 million in Q1 2026 per VOR's latest filing, from $628.4 million in the prior quarter.
- Across five years, Total Liabilities topped out at $2.4 billion in Q3 2025 and bottomed at $39.8 million in Q1 2022.
- Historically, Total Liabilities has averaged $352.6 million across 5 years, with a median of $47.4 million in 2023.
- Annual changes were most pronounced in 2024 — Total Liabilities decreased 10.79% — and 2025, when it surged 5480.73%.
- Vor Biopharma's Total Liabilities stood at $48.8 million in 2022, then fell by 2.78% to $47.4 million in 2023, then fell by 2.48% to $46.2 million in 2024, then soared by 1259.46% to $628.4 million in 2025, then advanced by 4.57% to $657.2 million in 2026.
- Business Quant data shows VOR's Total Liabilities at $657.2 million in Q1 2026, $628.4 million in Q4 2025, and $2.4 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Vor Biopharma | 1.36 Bn | 1.36 Bn | - | 681.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 681.25 Mn |
| Mar 31, 2026 | 657.17 Mn |
| Dec 31, 2025 | 628.44 Mn |
| Sep 30, 2025 | 2.40 Bn |
| Jun 30, 2025 | 1.71 Bn |
| Mar 31, 2025 | 43.24 Mn |
| Dec 31, 2024 | 46.23 Mn |
| Sep 30, 2024 | 43.04 Mn |
| Jun 30, 2024 | 43.51 Mn |
| Mar 31, 2024 | 44.00 Mn |
| Dec 31, 2023 | 47.40 Mn |
| Sep 30, 2023 | 48.24 Mn |
| Jun 30, 2023 | 46.54 Mn |
| Mar 31, 2023 | 47.32 Mn |
| Dec 31, 2022 | 48.76 Mn |
| Sep 30, 2022 | 47.64 Mn |
| Jun 30, 2022 | 49.64 Mn |
| Mar 31, 2022 | 39.82 Mn |
| Dec 31, 2021 | 26.33 Mn |
| Sep 30, 2021 | 25.68 Mn |